Document Preview Unavailable
First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
Po‐Lan Su; Chian‐Wei Chen; Yi‐Lin Wu; Chien‐Chung Lin; Wu‐Chou Su. Thoracic Cancer Vol. 12, Iss. 3, (Feb 2021): 287-296.You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library